# From intravenous access to subcutaneous tissue: advances in ketamine administration for treatment-resistant depression - URL: https://alisanburak.com/en/wcp-2026-posterler/ev0810 - Language: en - Last updated: not specified - Page title: From intravenous access to subcutaneous tissue: advances in ketamine administration for treatment-resistant depression | WCP 2026 Summary > Subcutaneous ketamine is emerging as a scalable option for treatment-resistant depression, offering rapid antidepressant effects, acceptable tolerability, and… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/ev0810) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. EV0810 E-PosterPsychopharmacologyReview # From intravenous access to subcutaneous tissue: advances in ketamine administration for treatment-resistant depression FROM VENOUS ACCESS TO SUBCUTANEOUS TISSUE: ADVANCES IN THE ADMINISTRATION OF KETAMINE FOR TREATMENT-RESISTANT DEPRESSION Presenter: Otto Feuerschuette Country: Brazil Subcutaneous ketamine is emerging as a scalable option for treatment-resistant depression, offering rapid antidepressant effects, acceptable tolerability, and simpler administration while eliminating the need for intravenous access. The aim of the study is to bring together evidence on the efficacy, safety, and practical advantages of administering subcutaneous (SC) ketamine and esketamine for treatment-resistant depression (TRD). A narrative evidence synthesis was conducted, encompassing randomized, open-label, retrospective, and pharmacokinetic studies, case series, and systematic reviews; antidepressant response, remission, tolerability, suicidal ideation, dose titration, and feasibility were assessed as outcomes. Background data indicate that TRD affects approximately 20% to 30% of patients with major depressive disorder, while ketamine is positioned as a rapid-acting antidepressant that provides clinically meaningful improvement within hours or days. Its proposed mechanism involves rapid antidepressant effects mediated by NMDA receptor blockade, increased glutamate levels, AMPA receptor activation, increased BDNF and mTOR signaling, synaptogenesis, and neuroplasticity. The evidence highlighted in the poster includes a response rate of 52.17%, a remission rate of 34.78%, and a rapid clinical effect emerging within 24 hours or less. The randomized KADS trial demonstrated clinically meaningful antidepressant improvement with repeated subcutaneous racemic ketamine, particularly when gradual dose titration was used; treatment was generally well tolerated, with mostly transient adverse effects, and eliminated the need for intravenous access. Regarding safety, dissociative and psychotomimetic symptoms are reported to be generally short-lived and to resolve spontaneously, while increases in blood pressure are mild, predictable, and self-limiting. The available evidence is noted to be limited by small samples, heterogeneous protocols, short follow-up periods, and the small number of studies directly comparing subcutaneous and intravenous administration, underscoring the need for larger, multicenter randomized trials. In conclusion, the subcutaneous route is proposed to expand access to rapid-acting antidepressant treatment by reducing the need for complex infusion infrastructure and intravenous access. [View the original poster](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2275) How to cite this study APA 7: Rezin, G. T., Marcon, J. V. M., Pasquali, M. A. B., & Feuerschuette, O. (2026, September 23-26). From venous access to subcutaneous tissue: advances in the administration of ketamine for treatment-resistant depression [E-poster]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2275 Vancouver: Rezin GT, Marcon JVM, Pasquali MAB, Feuerschuette O. From venous access to subcutaneous tissue: advances in the administration of ketamine for treatment-resistant depression [e-poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2275 Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/ev0810 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim